The Same Question, One Quarter Later
The Same Question, One Quarter Later
Medexus Pharmaceuticals reported fiscal Q2 2027 on November 12 and delivered exactly what the model required: total net revenue of $29.1 million against $24.7 million a year ago, adjusted EBITDA of $5.1 million versus $4.4 million, net income of $800 thousand versus a $300 thousand loss, and $5.4 million of operating cash flow. The commercialization of GRAFAPEX generated $5.7 million of product-level net revenue. Everything is up, and yet the single most important number on the call did not move at all: fiscal 2027 GRAFAPEX product-level net revenue guidance of $30 million to $32 million.
That is the tension. The first half of the fiscal year produced roughly $10.6 million of GRAFAPEX product-level revenue ($4.9 million in Q1 per the prior call, $5.7 million in Q2). To hit the low end of guidance, the December and March quarters must together deliver roughly $19-20 million — nearly double the first half, with the March quarter alone plausibly needing $11 million-plus. Scott Henry of Alliance Global asked precisely that, and his question is worth reading in full because it is the entire investment case in one sentence:
to get $30 million to $32 million, is going to take a significant jump from what we saw in the first half of the year, not just continuation of trends. What are you seeing that gives you confidence that you know, we are not just continuing to have the good things happen, but they are actually going to accelerate.
He asked a near-identical question one quarter ago, in August, when guidance was first set against a $5 million first quarter. What is revealing is not the question's persistence but the answer's evolution.
What Actually Changed: The Justification, Not the Number
In August, Kenneth d'Entremont leaned on the classic launch playbook — leading indicators, formulary listings, payer support, first hospital use:
“the reason we have confidence in the $30 million to $32 million is because of the leading indicators, which are obviously formulary listings, commercial support from the payers and then finally, first use from the hospitals.” — Kenneth d'Entremont, Chief Executive Officer · 2026-08-11This quarter, the answer is different in kind: he is now arguing that the US market needs to generate its own clinical evidence, and that evidence arrives at ASH in early December and at Tandem thereafter.
“we have now gotten to a point where there is evidence that is being generated from The US market that will be shared beginning at ASH and then obviously through tandem. So that is what gives us, you know, strong belief that we will see an acceleration in our revenues as real world evidence, from The US market. Starts to be shared.” — Kenneth d'Entremont, Chief Executive Officer · 2026-11-12This is a genuinely different thesis. In August it was access mechanics — is the drug on formulary, will payers pay, has anyone ordered. Now it is credibility diffusion — transplanters need to hear their peers at other US institutions report outcomes before the laggards convert. That reframing is intellectually honest, and it also pushes the burden of proof onto a calendar event roughly four weeks out, with the fiscal year ending March 31. He conceded the shape explicitly: “I think it will be spread over the 2 quarters.” — Kenneth d'Entremont, Chief Executive Officer · 2026-11-12
The operating metrics moved, but less than the rhetoric. Wholesaler data as of September 30 shows 86 individual health care institutions have ordered GRAFAPEX, up from 74 of roughly 180 addressable centers disclosed in June. However, the repeat-order disclosure narrowed in a way worth flagging: 38 of those 86 institutions placed multiple orders in the most recently completed six-month period. In February, management was touting a 77% reorder rate and talking about the trajectory toward 100%: “it's 77%, but absolutely... as new initiations of hospitals flatten, it should go closer to 100.” — Kenneth d'Entremont, Chief Executive Officer · 2026-02-12 That clean percentage has been retired in favour of a six-month cumulative count that is harder to compare — a small thing, but the kind of small thing that matters when guidance depends on depth of adoption rather than breadth.
Underlying demand is the cleanest number in the release, and Brendon Buschman framed it plainly: “Underlying, patient demand was $5.6 million for fiscal Q2 2020 7, representing growth of 16% compared to $4.8 million for fiscal Q1 2027, and 156% compared to $2.1 million for fiscal Q2 2020.” — Brendon Buschman, Chief Financial Officer · 2026-11-12 Low-teens sequential growth is a good business. It is not a business that doubles in two quarters without a step-change, which is exactly why the ASH evidence narrative has to carry the weight.
The Economics Behind the Headline
The $700 thousand year-over-year EBITDA increase is, almost precisely, GRAFAPEX's contribution: $5.7 million of product revenue less $3.8 million of personnel and infrastructure build plus $700 thousand of cost of sales before amortization. Read that way, the growth product is currently paying for its own launch and roughly nothing more. The stable base business — Rasuvo, IXINITY, the Canadian portfolio — is doing the heavy lifting on profitability while absorbing generic erosion on Rupall, which is why adjusted gross margin slipped to 64.0% from 65.2% on IXINITY's higher cost of sales despite GRAFAPEX being the highest-margin item in the bag.
The financial position remains the least controversial part of the story: net debt of $17.9 million, up $2.1 million since March 31 as working capital builds behind the launch, against net debt to adjusted EBITDA of 0.97x. On the prior call, Buschman said he would be comfortable returning toward the 3x range historically used. That is a company signalling it intends to buy something, and the UM171 licence is the template.
UM171 is where the call got most interesting, and least informative. The European conditional marketing authorization secured by Xcelthera gives Medexus a possible accelerated Health Canada pathway for patients without a donor, but d'Entremont was clear the agency has not confirmed it: “first step in Canada is getting clarity from Health Canada on what paths are available to us.” — Kenneth d'Entremont, Chief Executive Officer · 2026-11-12 That is the same answer he gave in August, when he also cautioned: “We're optimistic that we'll be able to find an expedited path, but there's no guarantee on that until we negotiate that with the agency.” — Kenneth d'Entremont, Chief Executive Officer · 2026-08-11 Launch guidance remains 2028 to 2031, unchanged from June. On US rights — the obvious value unlock — he declined entirely: “I cannot really comment on licensing discussions that might be ongoing.” — Kenneth d'Entremont, Chief Executive Officer · 2026-11-12
What Management Stopped Talking About
The keyword record is instructive. UM171 cell therapy was a top-five theme on the August call and has fallen out of this quarter's top set despite being the subject of two analyst questions — a symptom of a narrative that has been fully told and is now waiting on a regulator. royalty revenue, a top-ranked item in August thanks to the Gleolan tail, has vanished as expected. And the tariff discussion — a fixture of the August Q&A, with a 15% duty on Rasuvo and a possible orphan-drug carve-out for GRAFAPEX — is absent from this quarter's keyword set entirely.
That silence is conspicuous against the global backdrop. Tariff Refund was the single hottest market keyword in one recent quarter, and the recent reporter set is littered with companies booking refunds and net refund benefits — consumer and industrial names alike. Medexus, which imports Rasuvo from Germany and GRAFAPEX from Medac, said nothing. The base case remains a 15% tariff on cost of goods that management has repeatedly called immaterial, and the orphan-drug carve-out was genuinely uncertain, so silence is defensible. It is still a theme the market is paying for and this company is no longer discussing.
What replaced it in the company's keyword profile is telling: a heavy weighting of financial boilerplate — financial position, cash from operations, related non-GAAP measures, forward-looking language. Some of that is the IR script. But it also fits a quarter where the news was continuity rather than revelation, and where the differentiating language — early indicators, payer coverage, payer and access trends — is now a year old and fully priced into the narrative.
The Verdict
Medexus at roughly $125 million market cap is a single-asset launch story with a genuinely differentiated product, a real reimbursement tailwind, and a guidance number that has now survived three consecutive settings without being raised. The bull case requires a December inflection validated by conference data and a March quarter that is nearly double the September quarter. The bear case is that low-teens sequential demand growth is the actual slope of the curve, that 38 multi-order institutions out of 86 is thinner than a 77% reorder rate sounded, and that the base business is flat enough that any GRAFAPEX shortfall has nothing to hide behind.
Nothing in this quarter broke the thesis. Nothing in it proved it either. The company has effectively converted a formulary-execution story into an event-driven one, and the next six weeks will tell you whether the transplant community shows up in December.